Abbott Laboratories (ABT) is overvalued and Boston Scientific Corp (BSX) is undervalued.
Against our estimates of intrinsic value, BSX trades at the wider discount: a margin of safety of +30%, against -48% for ABT.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $70.00; the price of $103.69 is 48% above that value, and 78% of that value comes from beyond year five.
Leak Score 57/100 on 10 of 12 signals
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $64.12; the price of $44.92 is 30% below that value, and 80% of that value comes from beyond year five.
Leak Score 73/100 on 10 of 12 signals
| Metric | ABT | BSX |
|---|---|---|
| Verdict | Overvalued | Undervalued |
| Price | $103.69 | $44.92 |
| Intrinsic value | $70.00 | $64.12 |
| Margin of safety | -48% | +30% |
| Leak Score | 57/100 (10/12) | 73/100 (10/12) |
| Market cap | $179.4B | $65.1B |
| Revenue growth, 5 years | 5.1% | 15.2% |
| Operating margin | 16.4% | 21.8% |
| Net margin | 11.6% | 17.5% |
| Return on equity | 10.6% | 15.5% |
| Debt to equity | 0.64 | 0.51 |
| P/E | 33.5x | 18.2x |
| Forward P/E | 17.1x | 13.2x |
| P/B | 3.5x | 2.6x |
| Dividend yield | 2.5% | — |